Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory cytokines. PD-L1 expression levels on cancer cells m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xinfang Yu, Wei Li, Ken H. Young, Yong Li
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	programmed death-ligand 1 programmed death 1 posttranslational modifications stability translocation immunotherapy Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/e72adc11f98441168fc82fd608e91a33
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e72adc11f98441168fc82fd608e91a33
record_format	dspace
spelling	oai:doaj.org-article:e72adc11f98441168fc82fd608e91a332021-11-25T16:50:59ZPosttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave10.3390/biomedicines91117022227-9059https://doaj.org/article/e72adc11f98441168fc82fd608e91a332021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1702https://doaj.org/toc/2227-9059Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory cytokines. PD-L1 expression levels on cancer cells might affect the clinical response to anti-PD-1/PD-L1 therapies. Hence, understanding molecular mechanisms for regulating PD-L1 expression is essential for improving the clinical response rate and efficacy of PD-1/PD-L1 blockade. Posttranslational modifications (PTMs), including phosphorylation, glycosylation, ubiquitination, and acetylation, regulate PD-L1 stability, cellular translocation, and interaction with its receptor. A coordinated positive and negative regulation via PTMs is required to ensure the balance and function of the PD-L1 protein. In this review, we primarily focus on the roles of PTMs in PD-L1 expression, trafficking, and antitumor immune response. We also discuss the implication of PTMs in anti-PD-1/PD-L1 therapies.Xinfang YuWei LiKen H. YoungYong LiMDPI AGarticleprogrammed death-ligand 1programmed death 1posttranslational modificationsstabilitytranslocationimmunotherapyBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1702, p 1702 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	programmed death-ligand 1 programmed death 1 posttranslational modifications stability translocation immunotherapy Biology (General) QH301-705.5
spellingShingle	programmed death-ligand 1 programmed death 1 posttranslational modifications stability translocation immunotherapy Biology (General) QH301-705.5 Xinfang Yu Wei Li Ken H. Young Yong Li Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
description	Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory cytokines. PD-L1 expression levels on cancer cells might affect the clinical response to anti-PD-1/PD-L1 therapies. Hence, understanding molecular mechanisms for regulating PD-L1 expression is essential for improving the clinical response rate and efficacy of PD-1/PD-L1 blockade. Posttranslational modifications (PTMs), including phosphorylation, glycosylation, ubiquitination, and acetylation, regulate PD-L1 stability, cellular translocation, and interaction with its receptor. A coordinated positive and negative regulation via PTMs is required to ensure the balance and function of the PD-L1 protein. In this review, we primarily focus on the roles of PTMs in PD-L1 expression, trafficking, and antitumor immune response. We also discuss the implication of PTMs in anti-PD-1/PD-L1 therapies.
format	article
author	Xinfang Yu Wei Li Ken H. Young Yong Li
author_facet	Xinfang Yu Wei Li Ken H. Young Yong Li
author_sort	Xinfang Yu
title	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
title_short	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
title_full	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
title_fullStr	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
title_full_unstemmed	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
title_sort	posttranslational modifications in pd-l1 turnover and function: from cradle to grave
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e72adc11f98441168fc82fd608e91a33
work_keys_str_mv	AT xinfangyu posttranslationalmodificationsinpdl1turnoverandfunctionfromcradletograve AT weili posttranslationalmodificationsinpdl1turnoverandfunctionfromcradletograve AT kenhyoung posttranslationalmodificationsinpdl1turnoverandfunctionfromcradletograve AT yongli posttranslationalmodificationsinpdl1turnoverandfunctionfromcradletograve
_version_	1718412930272198656

Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave

Ejemplares similares